Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Capital Expenditures (2016 - 2025)

Tandem Diabetes Care's Capital Expenditures history spans 13 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 6.52% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $3.7 million, down 80.77%, while the annual FY2025 figure was $3.7 million, 80.77% down from the prior year.
  • Capital Expenditures reached $2.9 million in Q4 2025 per TNDM's latest filing, up from -$8.3 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $29.8 million in Q4 2022 to a low of -$18.7 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $3.1 million, with a median of $2.9 million recorded in 2025.
  • The largest YoY upside for Capital Expenditures was 33358.43% in 2022 against a maximum downside of 2217.85% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $89000.0 in 2021, then skyrocketed by 33358.43% to $29.8 million in 2022, then plummeted by 162.66% to -$18.7 million in 2023, then skyrocketed by 116.45% to $3.1 million in 2024, then dropped by 6.52% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Capital Expenditures are $2.9 million (Q4 2025), -$8.3 million (Q3 2025), and $6.2 million (Q2 2025).